AduPARE1A and gemcitabine combined treatment trigger synergistic antitumor effects in pancreatic cancer through NF-KB mediated uPAR activation

Molecular Cancer

Volumn 14, Issue 1, 2015, Pages

  Maliandi, Maria Victoria ^a,b   Mato Berciano, Ana ^a,b   Sobrevals, Luciano ^a,b   Roué, Gaël ^a   José, Anabel ^a,b   Fillat, Cristina ^a,b  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

Author keywords

Gemcitabine; NF KB; Oncolytic adenovirus; Pancreatic cancer; uPAR

Indexed keywords

GEMCITABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ONCOLYTIC ADENOVIRUS; UROKINASE RECEPTOR; DEOXYCYTIDINE; ONCOLYTIC VIRUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BXPC 3 CELL LINE; CANCER COMBINATION CHEMOTHERAPY; CELL VIABILITY; CONTROLLED STUDY; DRUG POTENTIATION; DRUG SENSITIZATION; GENE ACTIVATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MONOTHERAPY; MOUSE; MOUSE MODEL; NONHUMAN; PANC 1 CELL LINE; PANCREAS CANCER; PANCREATIC CANCER CELL LINE; PROMOTER REGION; PROTEIN DNA BINDING; PROTEIN INDUCTION; SINGLE DRUG DOSE; SURVIVAL; TRANSGENE; TUMOR GROWTH; TUMOR XENOGRAFT; VIRUS REPLICATION; ADENOVIRIDAE; ANALOGS AND DERIVATIVES; ANIMAL; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; METABOLISM; MORTALITY; MULTIMODALITY CANCER THERAPY; ONCOLYTIC VIROTHERAPY; PANCREATIC NEOPLASMS; PATHOLOGY; TUMOR CELL LINE;

ADENOVIRIDAE; MUS;

ADENOVIRIDAE; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MALE; MICE; NF-KAPPA B; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PANCREATIC NEOPLASMS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84938059114     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/s12943-015-0413-2     Document Type: Article

References (33)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9-29.
2. Hecht JR, Bedford R, Abbruzzese JL, Lahoti S, Reid TR, Soetikno RM, et al. A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin Cancer Res. 2003;9:555-61.
3. Huch M, Gros A, Jose A, Gonzalez JR, Alemany R, Fillat C. Urokinase-type plasminogen activator receptor transcriptionally controlled adenoviruses eradicate pancreatic tumors and liver metastasis in mouse models. Neoplasia. 2009;11:518-28. 514 p following 528.
4. Sobrevals L, Mato-Berciano A, Urtasun N, Mazo A, Fillat C. uPAR-controlled oncolytic adenoviruses eliminate cancer stem cells in human pancreatic tumors. Stem Cell Res. 2014;12:1-10.
5. Burris 3rd HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403-13.
6. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691-703.
7. Cherubini G, Kallin C, Mozetic A, Hammaren-Busch K, Muller H, Lemoine NR, et al. The oncolytic adenovirus AdDeltaDelta enhances selective cancer cell killing in combination with DNA-damaging drugs in pancreatic cancer models. Gene Ther. 2011;18:1157-65.
8. Leitner S, Sweeney K, Oberg D, Davies D, Miranda E, Lemoine NR, et al. Oncolytic adenoviral mutants with E1B19K gene deletions enhance gemcitabine-induced apoptosis in pancreatic carcinoma cells and anti-tumor efficacy in vivo. Clin Cancer Res. 2009;15:1730-40.
9. Nelson AR, Davydova J, Curiel DT, Yamamoto M. Combination of conditionally replicative adenovirus and standard chemotherapies shows synergistic antitumor effect in pancreatic cancer. Cancer Sci. 2009;100:2181-7.
10. Onimaru M, Ohuchida K, Nagai E, Mizumoto K, Egami T, Cui L, et al. Combination with low-dose gemcitabine and hTERT-promoter-dependent conditionally replicative adenovirus enhances cytotoxicity through their crosstalk mechanisms in pancreatic cancer. Cancer Lett. 2010;294:178-86.
11. Kim MK, Jeon YK, Woo JK, Choi Y, Choi DH, Kim YH, et al. The C-terminal region of Bfl-1 sensitizes non-small cell lung cancer to gemcitabine-induced apoptosis by suppressing NF-kappaB activity and down-regulating Bfl-1. Mol Cancer. 2011;10:98.
12. Rejiba S, Bigand C, Parmentier C, Hajri A. Gemcitabine-based chemogene therapy for pancreatic cancer using Ad-dCK::UMK GDEPT and TS/RR siRNA strategies. Neoplasia. 2009;11:637-50.
13. Wang Y, Dang J, Wang H, Allgayer H, Murrell GA, Boyd D. Identification of a novel nuclear factor-kappaB sequence involved in expression of urokinase-type plasminogen activator receptor. Eur J Biochem. 2000;267:3248-54.
14. Li F, Sethi G. Targeting transcription factor NF-kappaB to overcome chemoresistance and radioresistance in cancer therapy. Biochim Biophys Acta. 1805;2010:167-80.
15. Fillat C, Maliandi MV, Mato-Berciano A, Alemany R. Combining oncolytic virotherapy and cytotoxic therapies to fight cancer. Curr Pharm Des. 2014;20:6513-21.
16. Wennier S, Li S, McFadden G. Oncolytic virotherapy for pancreatic cancer. Expert Rev Mol Med. 2011;13:e18.
17. Sheridan C. First oncolytic virus edges towards approval in surprise vote. Nat Biotechnol. 2015;33:569-70.
18. Watanabe I, Kasuya H, Nomura N, Shikano T, Shirota T, Kanazumi N, et al. Effects of tumor selective replication-competent herpes viruses in combination with gemcitabine on pancreatic cancer. Cancer Chemother Pharmacol. 2008;61:875-82.
19. Bhattacharyya M, Francis J, Eddouadi A, Lemoine NR, Hallden G. An oncolytic adenovirus defective in pRb-binding (dl922-947) can efficiently eliminate pancreatic cancer cells and tumors in vivo in combination with 5-FU or gemcitabine. Cancer Gene Ther. 2011;18:734-43.
20. Liu D, Kojima T, Ouchi M, Kuroda S, Watanabe Y, Hashimoto Y, et al. Preclinical evaluation of synergistic effect of telomerase-specific oncolytic virotherapy and gemcitabine for human lung cancer. Mol Cancer Ther. 2009;8:980-7.
21. Yamaguchi H, Chen CT, Chou CK, Pal A, Bornmann W, Hortobagyi GN, et al. Adenovirus 5 E1A enhances histone deacetylase inhibitors-induced apoptosis through Egr-1-mediated Bim upregulation. Oncogene. 2010;29:5619-29.
22. Frisch SM. E1A as a tumor suppressor gene: commentary re S. Madhusudan et al. A multicenter Phase I gene therapy clinical trial involving intraperitoneal administration of E1A-lipid complex in patients with recurrent epithelial ovarian cancer overexpressing HER-2/neu oncogene. Clin Cancer Res. 2004;10:2905-7.
23. Garcia-Rodriguez L, Perez-Torras S, Carrio M, Cascante A, Garcia-Ribas I, Mazo A, et al. Connexin-26 is a key factor mediating gemcitabine bystander effect. Mol Cancer Ther. 2011;10:505-17.
24. Hemminki A, Kanerva A, Liu B, Wang M, Alvarez RD, Siegal GP, et al. Modulation of coxsackie-adenovirus receptor expression for increased adenoviral transgene expression. Cancer Res. 2003;63:847-53.
25. Soravia E, Grebe A, De Luca P, Helin K, Suh TT, Degen JL, et al. A conserved TATA-less proximal promoter drives basal transcription from the urokinase-type plasminogen activator receptor gene. Blood. 1995;86:624-35.
26. de Sousa CL, Monteiro G. Gemcitabine: Metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer. Eur J Pharmacol. 2014;741C:8-16.
27. Lee WP, Tai DI, Tsai SL, Yeh CT, Chao Y, Lee SD, et al. Adenovirus type 5 E1A sensitizes hepatocellular carcinoma cells to gemcitabine. Cancer Res. 2003;63:6229-36.
28. Weber HL, Gidekel M, Werbajh S, Salvatierra E, Rotondaro C, Sganga L, et al. A novel CDC25B promoter based oncolytic adenovirus inhibited growth of orthotopic human pancreatic tumors in different preclinical models. Clin Cancer Res. 2015;21(7):1665-74.
29. Jose A, Sobrevals L, Ivorra A, Fillat C. Irreversible electroporation shows efficacy against pancreatic carcinoma without systemic toxicity in mouse models. Cancer Lett. 2012;317:16-23.
30. Jose A, Sobrevals L, Miguel Camacho-Sanchez J, Huch M, Andreu N, Ayuso E, et al. Intraductal delivery of adenoviruses targets pancreatic tumors in transgenic Ela-myc mice and orthotopic xenografts. Oncotarget. 2013;4:94-105.
31. Espinosa L, Cathelin S, D'Altri T, Trimarchi T, Statnikov A, Guiu J, et al. The Notch/Hes1 pathway sustains NF-kappaB activation through CYLD repression in T cell leukemia. Cancer Cell. 2010;18:268-81.
32. Abate-Daga D, Garcia-Rodriguez L, Sumoy L, Fillat C. Cell cycle control pathways act as conditioning factors for TK/GCV sensitivity in pancreatic cancer cells. Biochim Biophys Acta. 1803;2010:1175-85.
33. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27-55.